Venture Partner at Samsara BioCapital, and former CSO and COO of Karus Therapeutics, brings deep scientific and industry experience to Mosaic’s Executive Leadership team
· Stephen will lead the Company’s scientific strategy, preclinical pipeline build and R&D organisation
Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease
Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.
The United Kingdom Health Security Agency (UKHSA) is a system leader for health security; taking action internationally to strengthen global health security, providing trusted advice to government and the public and reducing inequalities in the way different communities experience and are impacted by infectious disease, environmental hazards, and other threats to health.
EDX Medical Ltd was founded by Professor Sir Chris Evans in early 2022 to provide a range of testing solutions from point of care to laboratory assays in a range of major diseases, including cancer, neurological disorders, cardio-metabolic and infectious diseases. Sir Chris was knighted for his services to the British biotechnology industry and is one of the UK’s leading entrepreneurs and investors, founding dozens of companies.
TTP is an employee-owned technology and product development consultancy, with a 40-year track record of partnering with ambitious clients to solve complex challenges and bring innovative, commercially successful solutions to market.
We invent, design, and manufacture impactful products and technologies across a wide range of industries – including healthcare, life science, energy, and communications – and at the intersection of engineering, physical science, and biology.
Join tranScrip’s expert panel as they explore how medical writing lies at the heart of every successful MAA, not as an afterthought, but as the driving force behind clarity, strategy, and collaboration from the very beginning.
The discussion will offer insider perspectives on what makes an exceptional MAA, how to achieve it, and how cross-functional expertise, spanning medical writing, regulatory, medical, and publishing teams, can transform complex data and processes into successful outcomes.
· Industry leader brings deep expertise across neurodegenerative disease therapeutics development
· Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB
Quotient Therapeutics Ltd is a privately held, early-stage company developing a novel genomics platform and therapeutics for diseases with a large unmet need.
Calling outstanding PhD Candidates who want to drive the future of biologic therapies...
...be among the very first in the world to use Qudos personal manufacturing as an oxidising Golgi-like production environment to precisely control glycosylation of next generation therapeutics.
We’re looking for a Research Scientist to undertake research projects which advance our understanding of the microbiome-gut-brain axis and its role in ageing. This role will be based in the group of Dr Aimee Parker in the Food, Microbiome and Health Programme at Quadram Institute.